Dr. Marcelo C. DaSilva, MD, FACS, FICS serves as the Senior Medical Reviewer for Mesothelioma Funds Administration. Dr. DaSilva is the Medical Director of Thoracic Surgery at AdventHealth Cancer Institute in Orlando, Florida, where he leads one of the most established mesothelioma treatment programs in the United States.
Background and experience
Dr. DaSilva has more than 25 years of experience caring for patients with mesothelioma and other thoracic malignancies. He is the founder of the Mesothelioma International Treatment Program at AdventHealth (established 2019) and is a recognized pioneer in heated intraoperative chemotherapy (HIOC) for mesothelioma. Prior to AdventHealth, Dr. DaSilva served on faculty at Harvard Medical School and at Brigham and Women’s Hospital.
Credentials
- MD — Doctor of Medicine
- FACS — Fellow of the American College of Surgeons
- FICS — Fellow of the International College of Surgeons
- Triple board-certified
- Specialty: Thoracic Surgical Oncology
Selected affiliations and references
What Dr. DaSilva reviews
Dr. DaSilva reviews medical content on this site for clinical accuracy. His role is to ensure that information we publish about mesothelioma — what it is, how it’s diagnosed, how it’s treated, what patients and families can expect — reflects current medical understanding. Dr. DaSilva does not endorse any specific legal claim, settlement, or outcome. Legal questions are addressed by Danziger & De Llano, LLP, the firm sponsoring this site.
Compensation and independence disclosure
Dr. DaSilva is independently compensated for his medical review services. His clinical and academic affiliations are independent of Mesothelioma Funds Administration and Danziger & De Llano, LLP. Dr. DaSilva does not have a financial interest in the outcome of any individual claim or case.
Medical sources cited on this site
Where medical or epidemiological figures appear on this site, we cite primary authorities — including:
- National Cancer Institute (NCI) — for mesothelioma definitions and current cancer statistics. cancer.gov/types/mesothelioma
- American Cancer Society (ACS) — for U.S. incidence and demographic figures (approximately 3,000 new mesothelioma diagnoses per year in the U.S.). cancer.org
- Agency for Toxic Substances and Disease Registry (ATSDR) — for asbestos toxicology, including the documented 30 to 40 year latency period from asbestos exposure to mesothelioma diagnosis. atsdr.cdc.gov
- Occupational Safety and Health Administration (OSHA) — for current asbestos exposure standards (Permissible Exposure Limit: 0.1 fibers per cubic centimeter, 8-hour TWA). osha.gov
- Environmental Protection Agency (EPA) — for current asbestos regulations, including the March 2024 final rule banning chrysotile asbestos. epa.gov
Statistics about asbestos trust fund claim values, settlement amounts, and litigation outcomes are described as “industry-tracked figures” rather than presented as government data when no primary federal source is available, and are sourced where possible from law firm aggregations such as published RAND analyses and trust administrator disclosures.